Clinical Trials Logo

Filter by:
NCT ID: NCT00255502 Completed - Hypertension Clinical Trials

307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects

Start date: July 2002
Phase: Phase 3
Study type: Interventional

This was a 52-week, multicenter, open-label study to determine the safety, tolerability and pharmacokinetics of TOPROL-XL (metoprolol succinate) extended-release tablets (metoprolol CR/XL) in hypertensive pediatric subjects. The study population included school age children (age 6 to 12 years < Tanner Stage 3) and adolescents (> 12 years old or > Tanner Stage 3 to 16 years old) of both genders. Because response to some therapies in adult hypertension appears to be different in black and non-black populations, the recruitment will have a mixture of black and non-black subjects. Pharmacokinetic measurements were performed on a subset of patients. Thirty subjects (15 subjects each in the 6 to 12 year age group and the 13 to 16 year age group) had a series of blood samples drawn. All subjects had a trough plasma level taken 24 hours after the last dose of open-label metoprolol CR/XL (Visit 18) with the exception of those subjects who completed Protocol 307B (16 week open-label treatment).

NCT ID: NCT00147589 Completed - Hypertension Clinical Trials

A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.

Start date: September 2004
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy, safety, and toleration of eplerenone in the treatment of children aged 6 to 16 years with high blood pressure. The study will last approximately 10 weeks and about 320 patients will participate.

NCT ID: NCT00140673 Completed - Clinical trials for Infections, Rotavirus

A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.

Start date: August 5, 2003
Phase: Phase 3
Study type: Interventional

The main objectives of this study are: 1) In a subset (N = 20 000), to determine vaccine efficacy against severe rotavirus (RV) gastroenteritis (GE) during the period starting from 2 weeks after Dose 2 until one year of age. 2) In all subjects (N = 60 000), to determine the safety of GSK Biologicals' HRV vaccine with respect to definite intussusception (IS) within 31 days (Day 0-Day 30) after each HRV vaccine dose.

NCT ID: NCT00139347 Completed - Clinical trials for Infections, Rotavirus

Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants

Start date: December 2003
Phase: Phase 3
Study type: Interventional

The main objectives of this study is to determine vaccine efficacy against severe rotavirus (RV) gastroenteritis (GE) during the period starting from 2 weeks after Dose 2 until one year of age.

NCT ID: NCT00070980 Completed - HIV Infections Clinical Trials

Massage to Increase Well-Being and Immune Function in Dominican Children Infected With HIV

Start date: March 2003
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether massage therapy can improve immune status and enhance well-being in children living in the Dominican Republic who are infected with HIV.

NCT ID: NCT00004999 Suspended - HIV Infections Clinical Trials

Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients

Start date: August 1999
Phase: Phase 2
Study type: Interventional

The purpose of this study is to look at the effectiveness of giving a new anti-HIV drug (AG1549) plus Viracept (nelfinavir) plus Combivir (a tablet containing zidovudine plus lamivudine) to HIV-infected patients who are not taking anti-HIV drugs.

NCT ID: NCT00004998 Suspended - HIV Infections Clinical Trials

Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

Start date: November 1999
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if two different doses of AG1549 plus other anti-HIV drugs are safe and effective in HIV-infected patients who are not taking anti-HIV drugs.

NCT ID: NCT00002399 Completed - HIV Infections Clinical Trials

A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the safety and effectiveness of SCH 56592 with that of fluconazole in the treatment of OPC (a fungal infection of the throat) in HIV-positive patients.